Conditions of use of ceftozolane / tazobactam (ZERBAXA®) in real life: a national prospective multicenter observational study FRESH-PEF73407-en Cécile ALEXANDRE Conditions of use of ceftozolane / tazobactam (ZERBAXA®) in real life: a national prospective multicenter observational study CONDUCT FRESH-PEF73407-en 73407 FRESH-PEF73407 Laurie LEVY-BACHELOT MSD FRANCE Epidemiology France Portal (PEF) MSD FRANCE null Laurie;LEVY-BACHELOT ZERBAXA ceftozolane tazobactam Infectious disease medicine Certain infectious or parasitic diseases Healthcare system determinants: Use of care Healthcare system determinants To describe the sociodemographic and clinical characteristics, management and clinical outcomes of hospitalized patients treated with ceftolozane/tazobactam in routine practice.null null France Individuals Patients population Male Female Infant, Newborn (birth to 28 days) Infant (28 days to 2 years) Child, Preschool (2 to 5 years) Child (6 to 12 years) Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) Clinical dataBiological dataSocio-demographic data Other Through organizations (health services or institutions schools businesses etc.) Other Observational Study Observational Study About 300 Unknown To be defined